{"id":78705,"date":"2024-08-09T22:17:32","date_gmt":"2024-08-09T22:17:32","guid":{"rendered":"https:\/\/one.sightlinemg.com\/airforcetimes\/uncategorized\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/"},"modified":"2026-08-08T16:00:14","modified_gmt":"2026-08-08T16:00:14","slug":"fda-rejects-psychedelic-mdma-as-treatment-for-ptsd","status":"publish","type":"post","link":"https:\/\/one.sightlinemg.com\/airforcetimes\/news\/your-air-force\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/","title":{"rendered":"FDA rejects psychedelic MDMA as treatment for PTSD"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Federal health regulators on Friday declined to approve the <a href=\"https:\/\/www.militarytimes.com\/news\/your-military\/2024\/02\/13\/psychedelic-to-receive-fast-track-review-as-possible-ptsd-drug\/\">psychedelic drug MDMA<\/a> as a therapy for PTSD, a major setback for groups, including veterans, seeking a breakthrough decision in favor of using mind-altering substances to treat serious mental health conditions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Drugmaker Lykos Therapeutics said the FDA notified the company that the drug \u201ccould not be approved based on data submitted to date,\u201d and requested an additional late-stage study. Such studies generally take several years and millions of dollars to conduct. The drugmaker said it plans to ask the agency to reconsider.<\/p>\n\n\n\t<aside class=\"smg-interstitial-link wp-block-smg-interstitial-link\">\n\t\t<a href=\"https:\/\/one.sightlinemg.com\/militarytimes\/news\/your-military\/2024\/07\/28\/veterans-push-for-psychedelic-therapy-but-mdma-application-struggles\/\" class=\"smg-interstitial-link__inner\">\n\t\t\t\t\t\t\t<div class=\"smg-interstitial-link__media\">\n\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"200\" src=\"https:\/\/one.sightlinemg.com\/wp-content\/uploads\/2026\/08\/Psychedelic_Therapy-Veterans_26963.jpg.jpg?w=300\" class=\"smg-interstitial-link__image wp-post-image\" alt=\"\" \/>\t\t\t\t<\/div>\n\t\t\t\t\t\t<div class=\"smg-interstitial-link__content\">\n\t\t\t\t<span class=\"smg-interstitial-link__kicker\">Related<\/span>\n\t\t\t\t<h3 class=\"smg-interstitial-link__title\">Veterans push for psychedelic therapy, but MDMA application struggles<\/h3>\n\t\t\t\t\t\t\t\t\t<p class=\"smg-interstitial-link__excerpt\">Veterans have spent years lobbying for the use of psychedelic drugs to treat PTSD, but a critical review of MDMA has put the therapy&#039;s approval in doubt.<\/p>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/a>\n\t<\/aside>\n\t\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.militarytimes.com\/news\/your-military\/2023\/11\/08\/psychedelics-may-soon-be-available-sort-of-to-treat-vets-with-ptsd\/\" target=\"_blank\">Lykos and other psychedelic companies<\/a> had hoped that MDMA would be approved and pave the way for other hallucinogenic drugs to enter the medical mainstream. If the FDA had granted the request, MDMA, also known as ecstasy or molly, would have become the first illegal psychedelic to become a federally approved medicine.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA\u2019s decision was expected after a panel of <a href=\"https:\/\/www.militarytimes.com\/news\/your-military\/2024\/06\/05\/fda-advisory-panel-votes-against-psychedelic-therapy-to-treat-ptsd\/\" target=\"_blank\">government advisors voted overwhelmingly against the drug\u2019s use<\/a> for post-traumatic stress disorder in June. The negative vote came after an all-day meeting in which experts scrutinized Lykos\u2019 study data, research methods and possible risks of the drug, including heart problems, injury and abuse.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">FDA said Friday the MDMA application had \u201csignificant limitations\u201d that \u201cprevent the agency from concluding that the drug is safe and effective for the proposed indication.\u201d The agency said it will continue encouraging \u201cinnovation for psychedelic treatments and other therapies to address these medical needs.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Lykos said the issues FDA raised in what\u2019s called a complete response letter echoed the concerns during the June meeting.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cThe FDA request for another study is deeply disappointing,&#8221; Lykos CEO Amy Emerson said Friday in a statement. \u201cOur heart breaks for the millions of military veterans, first responders, victims of sexual and domestic abuse and countless others suffering from PTSD who may now face more years without access to new treatment options.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Lykos is essentially a corporate spinoff of the nation\u2019s leading psychedelic advocacy group, the Multidisciplinary Association for Psychedelic Studies, or MAPS, which funded the initial studies of MDMA by raising millions of dollars from wealthy backers.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The group has been a pioneer in researching the medical use of psychedelics, which major pharmaceutical companies have been unwilling to fund. Two small studies submitted to the FDA suggested combining MDMA with talk therapy led to significant easing of PTSD symptoms.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Antidepressants are now the only FDA-approved drugs for post-traumatic stress disorder, which is closely linked to depression, anxiety and suicidal thinking and is more prevalent among women and veterans.<\/p>\n\n\n\t<aside class=\"smg-interstitial-link wp-block-smg-interstitial-link\">\n\t\t<a href=\"https:\/\/one.sightlinemg.com\/militarytimes\/news\/your-military\/2024\/05\/14\/psychedelic-therapy-data-speaks-for-itself-va-official-says\/\" class=\"smg-interstitial-link__inner\">\n\t\t\t\t\t\t\t<div class=\"smg-interstitial-link__media\">\n\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"200\" src=\"https:\/\/one.sightlinemg.com\/wp-content\/uploads\/2026\/08\/Horizons.jpeg.jpg?w=300\" class=\"smg-interstitial-link__image wp-post-image\" alt=\"\" \/>\t\t\t\t<\/div>\n\t\t\t\t\t\t<div class=\"smg-interstitial-link__content\">\n\t\t\t\t<span class=\"smg-interstitial-link__kicker\">Related<\/span>\n\t\t\t\t<h3 class=\"smg-interstitial-link__title\">Psychedelic therapy data \u2018speaks for itself,\u2019 VA official says<\/h3>\n\t\t\t\t\t\t\t\t\t<p class=\"smg-interstitial-link__excerpt\">The VA\u2019s top health official said the agency is prepared to spend \u201cat least in the millions\u201d on clinical trials of psychedelic therapies for PTSD.<\/p>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/a>\n\t<\/aside>\n\t\n\n\n<p class=\"wp-block-paragraph\">In recent years, MDMA research has been widely publicized by <a href=\"https:\/\/www.militarytimes.com\/news\/your-army\/2018\/05\/09\/psychedelic-drug-provides-relief-for-veterans-with-ptsd\/\" target=\"_blank\">combat veterans<\/a>, who say the lack of treatment options for PTSD has contributed to higher rates of suicide among military personnel. Last month, veterans supporting psychedelic therapy lobbied on Capitol Hill in support of the drug. And more than 80 House and Senate lawmakers have signed letters to the FDA in recent weeks urging MDMA\u2019s approval.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">But FDA\u2019s review brought new scrutiny to the research. The vast majority of patients in Lykos&#8217; studies correctly guessed whether they had received MDMA or a dummy pill, making it \u201cnearly impossible\u201d to maintain the \u201cblinding\u201d which is considered essential for medical research, according to FDA internal staffers.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In recent months, separate allegations of misconduct have emerged, including that some researchers involved in the studies coached patients to suppress negative results or inflate positive ones.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Despite the setback, many experts say other psychedelics may fare better before the agency.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">MDMA is the first in a series of psychedelics that are expected to be reviewed by the FDA in coming years as part of a resurgence of interesting into their therapeutic potential.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The idea of using psychedelics to enhance psychotherapy is not new. A handful of therapists in California used MDMA during the 1970s and 1980s \u2014 when it was still legal \u2014 to facilitate couples therapy sessions. MAPS was founded in 1986 to oppose a federal decision placing MDMA in the same ultra-restrictive drug category as heroin, LSD and other illegal psychedelics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">MAPS&#8217; studies of MDMA for PTSD began more than a decade ago. Since then, dozens of small, startup drugmakers have entered the field, studying other substances like psilocybin and LSD for conditions including depression, addiction and anxiety. Those studies are generally larger and more rigorous than the MDMA studies submitted to the FDA.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Two drug developers, Compass Pathways and Usona Institute, are conducting late-stage studies of psilocybin \u2014 the active ingredient in magic mushrooms \u2014 for severe depression.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><i>The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute\u2019s Science and Educational Media Group. The AP is solely responsible for all content.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>MDMA research has been widely publicized by combat veterans, who say limited PTSD treatment options have contributed to higher military suicide rates.<\/p>\n","protected":false},"author":7,"featured_media":110288,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","_yoast_wpseo_canonical":"","_acf":"","_yoast_wpseo_primary_category":67,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","_smg_distribution_targets":[]},"categories":[101,16,26,21,67],"tags":[],"coauthors":[7096],"class_list":["post-78705","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-daily-news-roundup","category-news","category-newsletters","category-veterans","category-your-air-force"],"acf":{"subheadline":"","legacy_arc_id":"MFRTQ3TYI5IVON3NNFVW26LOKB","arc_canonical_url":"\/news\/your-military\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/","remove_feature_photo":false,"is_sponsored":false,"subtype":"","redirect_url":"","disable_inline_ads":false,"native_logo_pretext":"Presented By:"},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA rejects psychedelic MDMA as treatment for PTSD - Air Force TImes<\/title>\n<meta name=\"description\" content=\"MDMA research has been widely publicized by combat veterans, who say limited PTSD treatment options have contributed to higher military suicide rates.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/one.sightlinemg.com\/militarytimes\/news\/your-military\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA rejects psychedelic MDMA as treatment for PTSD\" \/>\n<meta property=\"og:description\" content=\"MDMA research has been widely publicized by combat veterans, who say limited PTSD treatment options have contributed to higher military suicide rates.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/one.sightlinemg.com\/airforcetimes\/news\/your-air-force\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/\" \/>\n<meta property=\"og:site_name\" content=\"Air Force TImes\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-09T22:17:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-08T16:00:14+00:00\" \/>\n<meta name=\"author\" content=\"Matthew Perrone\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Matthew Perrone\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\n\t    \"@context\": \"https:\\\/\\\/schema.org\",\n\t    \"@graph\": [\n\t        {\n\t            \"@type\": \"Article\",\n\t            \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/news\\\/your-air-force\\\/2024\\\/08\\\/09\\\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\\\/#article\",\n\t            \"isPartOf\": {\n\t                \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/news\\\/your-air-force\\\/2024\\\/08\\\/09\\\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\\\/\"\n\t            },\n\t            \"author\": {\n\t                \"name\": \"migration\",\n\t                \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/#\\\/schema\\\/person\\\/cc76c831bb37a926738c8391fca7a3b1\"\n\t            },\n\t            \"headline\": \"FDA rejects psychedelic MDMA as treatment for PTSD\",\n\t            \"datePublished\": \"2024-08-09T22:17:32+00:00\",\n\t            \"dateModified\": \"2026-08-08T16:00:14+00:00\",\n\t            \"mainEntityOfPage\": {\n\t                \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/news\\\/your-air-force\\\/2024\\\/08\\\/09\\\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\\\/\"\n\t            },\n\t            \"wordCount\": 783,\n\t            \"commentCount\": 0,\n\t            \"publisher\": {\n\t                \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/#organization\"\n\t            },\n\t            \"image\": {\n\t                \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/news\\\/your-air-force\\\/2024\\\/08\\\/09\\\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\\\/#primaryimage\"\n\t            },\n\t            \"thumbnailUrl\": \"https:\\\/\\\/one.sightlinemg.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Psychedelic-Therapy_07104.jpg.jpg\",\n\t            \"articleSection\": [\n\t                \"Daily News Roundup\",\n\t                \"News\",\n\t                \"Newsletters\",\n\t                \"Veterans\",\n\t                \"Your Air Force\"\n\t            ],\n\t            \"inLanguage\": \"en-US\",\n\t            \"potentialAction\": [\n\t                {\n\t                    \"@type\": \"CommentAction\",\n\t                    \"name\": \"Comment\",\n\t                    \"target\": [\n\t                        \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/news\\\/your-air-force\\\/2024\\\/08\\\/09\\\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\\\/#respond\"\n\t                    ]\n\t                }\n\t            ]\n\t        },\n\t        {\n\t            \"@type\": \"WebPage\",\n\t            \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/news\\\/your-air-force\\\/2024\\\/08\\\/09\\\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\\\/\",\n\t            \"url\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/news\\\/your-air-force\\\/2024\\\/08\\\/09\\\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\\\/\",\n\t            \"name\": \"FDA rejects psychedelic MDMA as treatment for PTSD - Air Force TImes\",\n\t            \"isPartOf\": {\n\t                \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/#website\"\n\t            },\n\t            \"primaryImageOfPage\": {\n\t                \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/news\\\/your-air-force\\\/2024\\\/08\\\/09\\\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\\\/#primaryimage\"\n\t            },\n\t            \"image\": {\n\t                \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/news\\\/your-air-force\\\/2024\\\/08\\\/09\\\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\\\/#primaryimage\"\n\t            },\n\t            \"thumbnailUrl\": \"https:\\\/\\\/one.sightlinemg.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Psychedelic-Therapy_07104.jpg.jpg\",\n\t            \"datePublished\": \"2024-08-09T22:17:32+00:00\",\n\t            \"dateModified\": \"2026-08-08T16:00:14+00:00\",\n\t            \"description\": \"MDMA research has been widely publicized by combat veterans, who say limited PTSD treatment options have contributed to higher military suicide rates.\",\n\t            \"breadcrumb\": {\n\t                \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/news\\\/your-air-force\\\/2024\\\/08\\\/09\\\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\\\/#breadcrumb\"\n\t            },\n\t            \"inLanguage\": \"en-US\",\n\t            \"potentialAction\": [\n\t                {\n\t                    \"@type\": \"ReadAction\",\n\t                    \"target\": [\n\t                        \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/news\\\/your-air-force\\\/2024\\\/08\\\/09\\\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\\\/\"\n\t                    ]\n\t                }\n\t            ]\n\t        },\n\t        {\n\t            \"@type\": \"ImageObject\",\n\t            \"inLanguage\": \"en-US\",\n\t            \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/news\\\/your-air-force\\\/2024\\\/08\\\/09\\\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\\\/#primaryimage\",\n\t            \"url\": \"https:\\\/\\\/one.sightlinemg.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Psychedelic-Therapy_07104.jpg.jpg\",\n\t            \"contentUrl\": \"https:\\\/\\\/one.sightlinemg.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Psychedelic-Therapy_07104.jpg.jpg\"\n\t        },\n\t        {\n\t            \"@type\": \"BreadcrumbList\",\n\t            \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/news\\\/your-air-force\\\/2024\\\/08\\\/09\\\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\\\/#breadcrumb\",\n\t            \"itemListElement\": [\n\t                {\n\t                    \"@type\": \"ListItem\",\n\t                    \"position\": 1,\n\t                    \"name\": \"Home\",\n\t                    \"item\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/\",\n\t                    \"ad_zone\": \"home\"\n\t                },\n\t                {\n\t                    \"@type\": \"ListItem\",\n\t                    \"position\": 2,\n\t                    \"name\": \"Your Air Force\",\n\t                    \"item\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/news\\\/your-air-force\\\/\",\n\t                    \"ad_zone\": \"your-air-force\"\n\t                },\n\t                {\n\t                    \"@type\": \"ListItem\",\n\t                    \"position\": 3,\n\t                    \"name\": \"FDA rejects psychedelic MDMA as treatment for PTSD\"\n\t                }\n\t            ]\n\t        },\n\t        {\n\t            \"@type\": \"WebSite\",\n\t            \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/#website\",\n\t            \"url\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/\",\n\t            \"name\": \"Air Force TImes\",\n\t            \"description\": \"Independent News For Airmen | Air Force Times\",\n\t            \"publisher\": {\n\t                \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/#organization\"\n\t            },\n\t            \"potentialAction\": [\n\t                {\n\t                    \"@type\": \"SearchAction\",\n\t                    \"target\": {\n\t                        \"@type\": \"EntryPoint\",\n\t                        \"urlTemplate\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/?s={search_term_string}\"\n\t                    },\n\t                    \"query-input\": {\n\t                        \"@type\": \"PropertyValueSpecification\",\n\t                        \"valueRequired\": true,\n\t                        \"valueName\": \"search_term_string\"\n\t                    }\n\t                }\n\t            ],\n\t            \"inLanguage\": \"en-US\"\n\t        },\n\t        {\n\t            \"@type\": \"Organization\",\n\t            \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/#organization\",\n\t            \"name\": \"Air Force TImes\",\n\t            \"url\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/\",\n\t            \"logo\": {\n\t                \"@type\": \"ImageObject\",\n\t                \"inLanguage\": \"en-US\",\n\t                \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/#\\\/schema\\\/logo\\\/image\\\/\",\n\t                \"url\": \"https:\\\/\\\/one.sightlinemg.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/air-logo-white.png\",\n\t                \"contentUrl\": \"https:\\\/\\\/one.sightlinemg.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/air-logo-white.png\",\n\t                \"caption\": \"Air Force TImes\"\n\t            },\n\t            \"image\": {\n\t                \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/#\\\/schema\\\/logo\\\/image\\\/\"\n\t            }\n\t        },\n\t        {\n\t            \"@type\": \"Person\",\n\t            \"@id\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/#\\\/schema\\\/person\\\/cc76c831bb37a926738c8391fca7a3b1\",\n\t            \"name\": \"migration\",\n\t            \"image\": {\n\t                \"@type\": \"ImageObject\",\n\t                \"inLanguage\": \"en-US\",\n\t                \"@id\": \"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9e8d47be443ce94ce7fc357677b5f9c70235bb1f59e7267a102a74af58c04f59?s=96&d=mm&r=gcf4cb6ee0ec29e49e7a963234e4340ec\",\n\t                \"url\": \"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9e8d47be443ce94ce7fc357677b5f9c70235bb1f59e7267a102a74af58c04f59?s=96&d=mm&r=g\",\n\t                \"contentUrl\": \"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9e8d47be443ce94ce7fc357677b5f9c70235bb1f59e7267a102a74af58c04f59?s=96&d=mm&r=g\",\n\t                \"caption\": \"migration\"\n\t            },\n\t            \"url\": \"https:\\\/\\\/one.sightlinemg.com\\\/airforcetimes\\\/author\\\/migration\\\/\"\n\t        }\n\t    ]\n\t}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA rejects psychedelic MDMA as treatment for PTSD - Air Force TImes","description":"MDMA research has been widely publicized by combat veterans, who say limited PTSD treatment options have contributed to higher military suicide rates.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/one.sightlinemg.com\/militarytimes\/news\/your-military\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/","og_locale":"en_US","og_type":"article","og_title":"FDA rejects psychedelic MDMA as treatment for PTSD","og_description":"MDMA research has been widely publicized by combat veterans, who say limited PTSD treatment options have contributed to higher military suicide rates.","og_url":"https:\/\/one.sightlinemg.com\/airforcetimes\/news\/your-air-force\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/","og_site_name":"Air Force TImes","article_published_time":"2024-08-09T22:17:32+00:00","article_modified_time":"2026-08-08T16:00:14+00:00","author":"Matthew Perrone","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Matthew Perrone","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/news\/your-air-force\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/#article","isPartOf":{"@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/news\/your-air-force\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/"},"author":{"name":"migration","@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/#\/schema\/person\/cc76c831bb37a926738c8391fca7a3b1"},"headline":"FDA rejects psychedelic MDMA as treatment for PTSD","datePublished":"2024-08-09T22:17:32+00:00","dateModified":"2026-08-08T16:00:14+00:00","mainEntityOfPage":{"@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/news\/your-air-force\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/"},"wordCount":783,"commentCount":0,"publisher":{"@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/#organization"},"image":{"@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/news\/your-air-force\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/#primaryimage"},"thumbnailUrl":"https:\/\/one.sightlinemg.com\/wp-content\/uploads\/2026\/08\/Psychedelic-Therapy_07104.jpg.jpg","articleSection":["Daily News Roundup","News","Newsletters","Veterans","Your Air Force"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/one.sightlinemg.com\/airforcetimes\/news\/your-air-force\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/news\/your-air-force\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/","url":"https:\/\/one.sightlinemg.com\/airforcetimes\/news\/your-air-force\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/","name":"FDA rejects psychedelic MDMA as treatment for PTSD - Air Force TImes","isPartOf":{"@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/#website"},"primaryImageOfPage":{"@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/news\/your-air-force\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/#primaryimage"},"image":{"@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/news\/your-air-force\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/#primaryimage"},"thumbnailUrl":"https:\/\/one.sightlinemg.com\/wp-content\/uploads\/2026\/08\/Psychedelic-Therapy_07104.jpg.jpg","datePublished":"2024-08-09T22:17:32+00:00","dateModified":"2026-08-08T16:00:14+00:00","description":"MDMA research has been widely publicized by combat veterans, who say limited PTSD treatment options have contributed to higher military suicide rates.","breadcrumb":{"@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/news\/your-air-force\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/one.sightlinemg.com\/airforcetimes\/news\/your-air-force\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/news\/your-air-force\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/#primaryimage","url":"https:\/\/one.sightlinemg.com\/wp-content\/uploads\/2026\/08\/Psychedelic-Therapy_07104.jpg.jpg","contentUrl":"https:\/\/one.sightlinemg.com\/wp-content\/uploads\/2026\/08\/Psychedelic-Therapy_07104.jpg.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/news\/your-air-force\/2024\/08\/09\/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/one.sightlinemg.com\/airforcetimes\/","ad_zone":"home"},{"@type":"ListItem","position":2,"name":"Your Air Force","item":"https:\/\/one.sightlinemg.com\/airforcetimes\/news\/your-air-force\/","ad_zone":"your-air-force"},{"@type":"ListItem","position":3,"name":"FDA rejects psychedelic MDMA as treatment for PTSD"}]},{"@type":"WebSite","@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/#website","url":"https:\/\/one.sightlinemg.com\/airforcetimes\/","name":"Air Force TImes","description":"Independent News For Airmen | Air Force Times","publisher":{"@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/one.sightlinemg.com\/airforcetimes\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/#organization","name":"Air Force TImes","url":"https:\/\/one.sightlinemg.com\/airforcetimes\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/#\/schema\/logo\/image\/","url":"https:\/\/one.sightlinemg.com\/wp-content\/uploads\/2026\/06\/air-logo-white.png","contentUrl":"https:\/\/one.sightlinemg.com\/wp-content\/uploads\/2026\/06\/air-logo-white.png","caption":"Air Force TImes"},"image":{"@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/one.sightlinemg.com\/airforcetimes\/#\/schema\/person\/cc76c831bb37a926738c8391fca7a3b1","name":"migration","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9e8d47be443ce94ce7fc357677b5f9c70235bb1f59e7267a102a74af58c04f59?s=96&d=mm&r=gcf4cb6ee0ec29e49e7a963234e4340ec","url":"https:\/\/secure.gravatar.com\/avatar\/9e8d47be443ce94ce7fc357677b5f9c70235bb1f59e7267a102a74af58c04f59?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9e8d47be443ce94ce7fc357677b5f9c70235bb1f59e7267a102a74af58c04f59?s=96&d=mm&r=g","caption":"migration"},"url":"https:\/\/one.sightlinemg.com\/airforcetimes\/author\/migration\/"}]}},"jetpack_featured_media_url":"https:\/\/one.sightlinemg.com\/wp-content\/uploads\/2026\/08\/Psychedelic-Therapy_07104.jpg.jpg","jetpack_sharing_enabled":true,"distributor_meta":false,"distributor_terms":false,"distributor_media":false,"distributor_original_site_name":"Air Force TImes","distributor_original_site_url":"https:\/\/one.sightlinemg.com\/airforcetimes","push-errors":false,"_links":{"self":[{"href":"https:\/\/one.sightlinemg.com\/airforcetimes\/wp-json\/wp\/v2\/posts\/78705","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/one.sightlinemg.com\/airforcetimes\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/one.sightlinemg.com\/airforcetimes\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/one.sightlinemg.com\/airforcetimes\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/one.sightlinemg.com\/airforcetimes\/wp-json\/wp\/v2\/comments?post=78705"}],"version-history":[{"count":1,"href":"https:\/\/one.sightlinemg.com\/airforcetimes\/wp-json\/wp\/v2\/posts\/78705\/revisions"}],"predecessor-version":[{"id":78721,"href":"https:\/\/one.sightlinemg.com\/airforcetimes\/wp-json\/wp\/v2\/posts\/78705\/revisions\/78721"}],"wp:attachment":[{"href":"https:\/\/one.sightlinemg.com\/airforcetimes\/wp-json\/wp\/v2\/media?parent=78705"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/one.sightlinemg.com\/airforcetimes\/wp-json\/wp\/v2\/categories?post=78705"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/one.sightlinemg.com\/airforcetimes\/wp-json\/wp\/v2\/tags?post=78705"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/one.sightlinemg.com\/airforcetimes\/wp-json\/wp\/v2\/coauthors?post=78705"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}